Fundraising Fox
/Companies
Sign in

Mereo BioPharma Group

NASDAQ: MREO

London, GB · Founded 2015 · Incorporated in United Kingdom · 43 employees on LinkedIn · 4 known investors

Find your way into Mereo BioPharma Group

Sign up to see every warm intro you have to Mereo BioPharma Group

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Mereo BioPharma Group team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Mereo BioPharma is a biopharmaceutical company publicly traded on Nasdaq under the ticker MREO. This page presents its share price data and SEC filings for investors and commercial partners.

BiotechHealthtech

Founders & leadership

Mereo BioPharma Group was founded in 2015 by John Richard and Charles Sermon.

JRJohn Richard
John RichardHead of Corporate Development and Co-Founder
CS
Charles SermonGeneral Counsel and Co-Founder
RJRichard Jones
Richard JonesChief Financial Officer
JH
Jill HenrichSenior Vice President
DSDenise Scots-Knight
Denise Scots-KnightChief Executive Officer

Board

DD
Dr. Deepa PakianathanNon-Executive Director
DP
Dr. Peter FellnerChairman
KK
Kunal KashyapNon-Executive Director
PB
Paul BlackburnNon-Executive Director
PB
Peter BainsNon-Executive Director
MW
Michael WyzgaNon-Executive Director
DA
Dr. Anders EkblomNon-Executive Director

Investors · 4

Pontifax Venture Capitallisted by Pontifax Venture CapitalHerzeliya

How we know: Pontifax Venture Capital's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Vivo Capitallisted by Vivo CapitalPalo Alto · $10M – $50M

How we know: Vivo Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Woodford Investment Managementon the registerOxford

How we know: the Companies House PSC register · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$70M disclosed across 1 round · 2020

▶$70MraisedJun 2020 · 25 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Dr. Peter FellnerDirector
  • Richard JonesExecutive Officer, Director
  • Kunal KashyapDirector
  • Paul BlackburnDirector
  • John RichardExecutive Officer
  • Dr. Denise Scots-KnightExecutive Officer, Director
  • Jill HenrichExecutive Officer
  • Charles SermonExecutive Officer
  • Peter BainsDirector
  • Michael WyzgaDirector
  • Dr. Anders EkblomDirector
  • Dr. Deepa PakianathanDirector
  • Dr. Alastair MacKinnonExecutive Officer
Offering amount
$70M
Amount sold
$70M
Minimum investment
$1
Sales commissions
$4.2M
Placement agents
SVB Leerink LLC
First sale
Jun 2020
Incorporated
Other, United Kingdom
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 2

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.

Companies working in the same space as Mereo BioPharma Group.

Companies House · registry record

View on Companies House ↗
Registered name
MEREO BIOPHARMA GROUP PLC
Company number
09481161
Status
Active
Company type
Public limited company
Incorporated
10 Mar 2015
Registered office
4th Floor, One, Cavendish Place, London, W1G 0QF
Nature of business (SIC)
72110 — Research and experimental development on biotechnology
Previous names
MEREO BIOPHARMA GROUP LIMITED (2015–2016)
Accounts
last made up to 31 Dec 2025 · next due 30 Jun 2027
Confirmation statement
last made up to 23 Feb 2026 · next due 9 Mar 2027

Current officers · 10

  • Charles Edward Sermon — secretary, appointed 9 Nov 2023
  • Jeremy Bender — director, appointed 1 Oct 2020
  • Anders Ekblom — director, appointed 21 Apr 2015
  • Pierre Jacquet — director, appointed 20 Sept 2021
  • Deepika Pakianathan — director, appointed 23 Apr 2019
  • Justin Roberts — director, appointed 10 Nov 2022
  • Denise Vera Scots-Knight — director, appointed 10 Mar 2015
  • Daniel Shames — director, appointed 10 Nov 2022
  • Michael Wyzga — director, appointed 23 Apr 2019
  • Marc Yoskowitz — director, appointed 10 Nov 2022

Source: Companies House public register · retrieved 13 Sept 2026. Contains public sector information licensed under the Open Government Licence v3.0.

Frequently asked questions

What does Mereo BioPharma Group do?
Mereo BioPharma is a biopharmaceutical company publicly traded on Nasdaq under the ticker MREO. This page presents its share price data and SEC filings for investors and commercial partners.
Who founded Mereo BioPharma Group?
Mereo BioPharma Group was founded by John Richard, Charles Sermon in 2015.
Who are Mereo BioPharma Group's investors?
Mereo BioPharma Group's investors include Cancer Focus, Pontifax Venture Capital, Vivo Capital, Woodford Investment Management.
How much funding has Mereo BioPharma Group raised?
Mereo BioPharma Group has disclosed $70M raised across 1 round.
Where is Mereo BioPharma Group headquartered?
Mereo BioPharma Group is headquartered in London, GB.